[{"id":"2b2519dd-d5ad-49a5-8426-9dd154e0e010","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241392","created_at":"2022-02-15T15:52:47.825Z","updated_at":"2025-02-25T15:27:15.182Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT05241392","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/27/2022","start_date":" 01/27/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"},{"id":"29969cfe-2b37-4195-9895-8e10c1f2fc4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06482905","created_at":"2025-02-26T07:12:20.689Z","updated_at":"2025-02-26T07:12:20.689Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","source_id_and_acronym":"NCT06482905","lead_sponsor":"Tcelltech Inc.","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/04/2024","start_date":" 09/04/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-08"},{"id":"56e2e82d-0917-4545-b455-4c16a9d9c3bb","acronym":"CMD03","url":"https://clinicaltrials.gov/study/NCT06612645","created_at":"2025-02-26T10:08:23.382Z","updated_at":"2025-02-26T10:08:23.382Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors","source_id_and_acronym":"NCT06612645 - CMD03","lead_sponsor":"Chulalongkorn University","biomarkers":" IFNG • IL6 • CD276 • TNFA • IL2 • IL7R • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD276 • TNFA • IL2 • IL7R • IL10"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-12-09"},{"id":"0cc43d2c-924c-4915-b932-f4d78cd8e52d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06691308","created_at":"2025-02-26T13:54:17.106Z","updated_at":"2025-02-26T13:54:17.106Z","phase":"Phase 1","brief_title":"WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients","source_id_and_acronym":"NCT06691308","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 11/12/2024","start_date":" 11/12/2024","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-11-18"},{"id":"28391cf3-06f6-4d40-9f4d-4cb991363ec0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366179","created_at":"2022-05-09T11:56:25.996Z","updated_at":"2024-07-02T16:35:08.155Z","phase":"Phase 1","brief_title":"Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc","source_id_and_acronym":"NCT05366179","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR.B7-H3 T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 05/01/2030","study_completion_date":" 05/01/2030","last_update_posted":"2024-04-23"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"93b62ffd-6a53-4b40-8d89-301b6778ce44","acronym":"","url":"https://clinicaltrials.gov/study/NCT06158139","created_at":"2023-12-06T19:17:35.778Z","updated_at":"2024-07-02T16:35:08.151Z","phase":"Phase 1","brief_title":"Autologous CAR-T Cells Targeting B7-H3 in PDAC","source_id_and_acronym":"NCT06158139","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR.B7-H3 T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-04-23"},{"id":"9c7d7059-df8c-498d-839f-0cfa2f5fe9a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04670068","created_at":"2021-01-19T20:44:26.413Z","updated_at":"2024-07-02T16:35:08.066Z","phase":"Phase 1","brief_title":"Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian","source_id_and_acronym":"NCT04670068","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CD276 • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["CD276 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CAR.B7-H3 T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2024-04-23"},{"id":"3804b4a8-079f-4ab4-8ef9-6a11ceae4ce8","acronym":"CMD03DIPG","url":"https://clinicaltrials.gov/study/NCT06221553","created_at":"2024-01-24T17:20:41.108Z","updated_at":"2024-07-02T16:35:08.722Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG","source_id_and_acronym":"NCT06221553 - CMD03DIPG","lead_sponsor":"Chulalongkorn University","biomarkers":" CD276 • IL7R","pipe":"","alterations":" ","tags":["CD276 • IL7R"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-19"},{"id":"8692edc5-36b9-41d3-83ee-d4803fca127c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05835687","created_at":"2023-04-28T15:04:55.022Z","updated_at":"2024-07-02T16:35:14.889Z","phase":"Phase 1","brief_title":"Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors","source_id_and_acronym":"NCT05835687","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B7-H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-03-13"},{"id":"746dce89-6a8e-4752-947c-6bc43ac4a8ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185038","created_at":"2021-01-18T20:24:04.775Z","updated_at":"2024-07-02T16:35:25.602Z","phase":"Phase 1","brief_title":"Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT04185038","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCRI-CARB7H3(s)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2023-12-20"},{"id":"38a37beb-d929-43d0-9890-ba3737cd0325","acronym":"","url":"https://clinicaltrials.gov/study/NCT06018363","created_at":"2023-08-30T14:09:03.022Z","updated_at":"2024-07-02T16:35:38.641Z","phase":"Phase 1/2","brief_title":"Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection","source_id_and_acronym":"NCT06018363","lead_sponsor":"Dushu Lake Hospital Affiliated to Soochow University","biomarkers":" IL6 • CD276 • IL10","pipe":" | ","alterations":" CD276 expression","tags":["IL6 • CD276 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QH104"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-30"},{"id":"cc4fb18b-f792-4ae9-84d7-f106ddc4db2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897321","created_at":"2021-05-21T11:52:50.695Z","updated_at":"2024-07-02T16:35:40.645Z","phase":"Phase 1","brief_title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","source_id_and_acronym":"NCT04897321","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-08-08"},{"id":"23fcadf7-54f4-4f4c-83a0-f6b83e31d66d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05752877","created_at":"2023-03-03T15:01:30.598Z","updated_at":"2024-07-02T16:35:54.103Z","phase":"","brief_title":"Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma","source_id_and_acronym":"NCT05752877","lead_sponsor":"Second Affiliated Hospital of Soochow University","biomarkers":" PD-L1 • CD276","pipe":"","alterations":" ","tags":["PD-L1 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MT-026 • MT027"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-03-03"},{"id":"2ac1606a-0606-46ec-aac6-2458374bdc46","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341492","created_at":"2022-04-22T13:53:34.891Z","updated_at":"2024-07-02T16:35:54.546Z","phase":"Phase 1","brief_title":"EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05341492","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • CD276","pipe":" | ","alterations":" EGFR expression • CD276 expression","tags":["EGFR • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed EGFR/B7H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-02-28"},{"id":"05a3d63a-1145-4861-9039-4df131c43c8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05562024","created_at":"2022-09-30T19:56:03.957Z","updated_at":"2024-07-02T16:35:54.680Z","phase":"Phase 1","brief_title":"TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma","source_id_and_acronym":"NCT05562024","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA6-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 02/18/2039","study_completion_date":" 02/18/2039","last_update_posted":"2023-02-27"},{"id":"43102ae6-d1ea-4271-9690-90fe3e1581ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731219","created_at":"2023-02-16T15:00:35.996Z","updated_at":"2024-07-02T16:35:55.393Z","phase":"Phase 1","brief_title":"UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05731219","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2025","study_completion_date":" 09/26/2025","last_update_posted":"2023-02-16"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"ecf3418c-bacc-4bfa-8dfc-631284d39661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722171","created_at":"2023-02-10T15:00:14.965Z","updated_at":"2024-07-02T16:35:55.834Z","phase":"Phase 1","brief_title":"Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05722171","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2023-02-10"},{"id":"2b3e863c-cc9b-4df3-83a2-6eecb5cf291b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077866","created_at":"2021-01-18T19:58:10.932Z","updated_at":"2024-07-02T16:35:58.453Z","phase":"Phase 1/2","brief_title":"B7-H3 CAR-T for Recurrent or Refractory Glioblastoma","source_id_and_acronym":"NCT04077866","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • BP102"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-12-28"},{"id":"dc367bc1-2fb0-4ffe-9bd0-e5057ee3ca6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04385173","created_at":"2021-01-18T21:10:18.596Z","updated_at":"2024-07-02T16:35:58.461Z","phase":"Phase 1","brief_title":"Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma","source_id_and_acronym":"NCT04385173","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Airuituo (bevacizumab biosimilar) • BP102"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-28"},{"id":"b06978bc-9d94-4a02-8f57-068cf0ad4b28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515185","created_at":"2022-08-25T12:57:12.824Z","updated_at":"2024-07-02T16:36:04.865Z","phase":"Phase 1","brief_title":"B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors","source_id_and_acronym":"NCT05515185","lead_sponsor":"The First People's Hospital of Lianyungang","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • KT095"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 09/08/2024","primary_completion_date":" 09/08/2024","study_txt":" Completion: 09/08/2024","study_completion_date":" 09/08/2024","last_update_posted":"2022-08-25"},{"id":"22c4a7b3-005a-45aa-b942-f2db0868d6b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05323201","created_at":"2022-04-12T14:53:00.485Z","updated_at":"2024-07-02T16:36:13.151Z","phase":"Phase 1/2","brief_title":"Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer","source_id_and_acronym":"NCT05323201","lead_sponsor":"The Affiliated Hospital of Xuzhou Medical University","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • fhB7H3.CAR-Ts"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 02/10/2024","primary_completion_date":" 02/10/2024","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2022-04-12"},{"id":"faed0dd2-a4f9-464d-8199-fe65794a9804","acronym":"","url":"https://clinicaltrials.gov/study/NCT05211557","created_at":"2022-01-29T18:05:02.809Z","updated_at":"2024-07-02T16:36:17.869Z","phase":"Phase 1/2","brief_title":"Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer","source_id_and_acronym":"NCT05211557","lead_sponsor":"The Affiliated Hospital of Xuzhou Medical University","biomarkers":" CD276 • MUC16","pipe":" | ","alterations":" CD276 expression","tags":["CD276 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fhB7H3.CAR-Ts"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2022-01-27"}]